The global Parkinson's disease treatments market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of Parkinson's disease and rising awareness about the condition. The dopamine agonists segment accounted for the largest share in the global market in 2018, followed by levodopa and glutamate antagonists. Dopamine agonists are used for treating Parkinson's disease symptoms such as tremors, stiffness, slowness of movement, and difficulty with balance or walking. Levodopa is used for treating Parkinson's disease symptoms such as tremor and rigidity while glutamate antagonists are used for treating Parkinson's disease symptoms such as muscle spasms or stiffness.
North America accounted for the largest share in the global market in 2018 due to high prevalence rates of this condition among people aged 65 years or older population coupled with high healthcare expenditure per capita on treatment options available in this region. Asia Pacific is expected to witness fastest growth during forecast period owing to increasing awareness about this condition coupled with growing geriatric population base across countries like China and India which will lead to increased incidence rates over time.
-The number of people with Parkinson's Disease is expected to increase by 50% in the next 20 years.
-There are no known cures for Parkinson's Disease, but there are treatments available to help manage symptoms.
-The most common treatment for Parkinson's Disease is medication which can be taken orally or injected into the bloodstream.
Industry Growth Insights published a new data on “Parkinson's Disease Treatments Market”. The research report is titled “Parkinson's Disease Treatments Market research by Types (Dopamine Agonists, Levodopa, Glutamate Antagonist, Apomorphine, COMT Inhibitors Anticholinergics, MAO-B Inhibitors, Other Drugs), By Applications (Hospitals, Healthcare Institutes, Others), By Players/Companies GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma, Wockhardt, Acadia, UCB”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Parkinson's Disease Treatments Market Research Report
By Type
Dopamine Agonists, Levodopa, Glutamate Antagonist, Apomorphine, COMT Inhibitors Anticholinergics, MAO-B Inhibitors, Other Drugs
By Application
Hospitals, Healthcare Institutes, Others
By Companies
GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma, Wockhardt, Acadia, UCB
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Parkinson's Disease Treatments Market Report Segments:
The global Parkinson's Disease Treatments market is segmented on the basis of:
Types
Dopamine Agonists, Levodopa, Glutamate Antagonist, Apomorphine, COMT Inhibitors Anticholinergics, MAO-B Inhibitors, Other Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Healthcare Institutes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Merck
- Novartis
- Teva
- Boehringer Ingelheim
- Impax
- Abbvie
- Valeant Pharmaceuticals
- Lundbeck
- Sun Pharma
- Wockhardt
- Acadia
- UCB
Highlights of The Parkinson's Disease Treatments Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dopamine Agonists
- Levodopa
- Glutamate Antagonist
- Apomorphine
- COMT Inhibitors Anticholinergics
- MAO-B Inhibitors
- Other Drugs
- By Application:
- Hospitals
- Healthcare Institutes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Parkinson's Disease Treatments Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Parkinson's Disease, but there are treatments that can help manage the symptoms. Treatment options may include medication, surgery, and physical therapy.
Some of the major players in the parkinson's disease treatments market are GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma, Wockhardt, Acadia, UCB.
The parkinson's disease treatments market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Parkinson's Disease Treatments Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Parkinson's Disease Treatments Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Parkinson's Disease Treatments Market - Supply Chain
4.5. Global Parkinson's Disease Treatments Market Forecast
4.5.1. Parkinson's Disease Treatments Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Parkinson's Disease Treatments Market Size (000 Units) and Y-o-Y Growth
4.5.3. Parkinson's Disease Treatments Market Absolute $ Opportunity
5. Global Parkinson's Disease Treatments Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Parkinson's Disease Treatments Market Size and Volume Forecast by Type
5.3.1. Dopamine Agonists
5.3.2. Levodopa
5.3.3. Glutamate Antagonist
5.3.4. Apomorphine
5.3.5. COMT Inhibitors Anticholinergics
5.3.6. MAO-B Inhibitors
5.3.7. Other Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Parkinson's Disease Treatments Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Parkinson's Disease Treatments Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Healthcare Institutes
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Parkinson's Disease Treatments Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Parkinson's Disease Treatments Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Parkinson's Disease Treatments Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Parkinson's Disease Treatments Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Parkinson's Disease Treatments Demand Share Forecast, 2019-2026
9. North America Parkinson's Disease Treatments Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Parkinson's Disease Treatments Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Parkinson's Disease Treatments Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Healthcare Institutes
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Parkinson's Disease Treatments Market Size and Volume Forecast by Type
9.7.1. Dopamine Agonists
9.7.2. Levodopa
9.7.3. Glutamate Antagonist
9.7.4. Apomorphine
9.7.5. COMT Inhibitors Anticholinergics
9.7.6. MAO-B Inhibitors
9.7.7. Other Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Parkinson's Disease Treatments Demand Share Forecast, 2019-2026
10. Latin America Parkinson's Disease Treatments Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Parkinson's Disease Treatments Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Parkinson's Disease Treatments Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Healthcare Institutes
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Parkinson's Disease Treatments Market Size and Volume Forecast by Type
10.7.1. Dopamine Agonists
10.7.2. Levodopa
10.7.3. Glutamate Antagonist
10.7.4. Apomorphine
10.7.5. COMT Inhibitors Anticholinergics
10.7.6. MAO-B Inhibitors
10.7.7. Other Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Parkinson's Disease Treatments Demand Share Forecast, 2019-2026
11. Europe Parkinson's Disease Treatments Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Parkinson's Disease Treatments Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Parkinson's Disease Treatments Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Healthcare Institutes
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Parkinson's Disease Treatments Market Size and Volume Forecast by Type
11.7.1. Dopamine Agonists
11.7.2. Levodopa
11.7.3. Glutamate Antagonist
11.7.4. Apomorphine
11.7.5. COMT Inhibitors Anticholinergics
11.7.6. MAO-B Inhibitors
11.7.7. Other Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Parkinson's Disease Treatments Demand Share, 2019-2026
12. Asia Pacific Parkinson's Disease Treatments Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Parkinson's Disease Treatments Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Parkinson's Disease Treatments Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Healthcare Institutes
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Parkinson's Disease Treatments Market Size and Volume Forecast by Type
12.7.1. Dopamine Agonists
12.7.2. Levodopa
12.7.3. Glutamate Antagonist
12.7.4. Apomorphine
12.7.5. COMT Inhibitors Anticholinergics
12.7.6. MAO-B Inhibitors
12.7.7. Other Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Parkinson's Disease Treatments Demand Share, 2019-2026
13. Middle East & Africa Parkinson's Disease Treatments Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Parkinson's Disease Treatments Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Parkinson's Disease Treatments Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Healthcare Institutes
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Parkinson's Disease Treatments Market Size and Volume Forecast by Type
13.7.1. Dopamine Agonists
13.7.2. Levodopa
13.7.3. Glutamate Antagonist
13.7.4. Apomorphine
13.7.5. COMT Inhibitors Anticholinergics
13.7.6. MAO-B Inhibitors
13.7.7. Other Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Parkinson's Disease Treatments Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Parkinson's Disease Treatments Market: Market Share Analysis
14.2. Parkinson's Disease Treatments Distributors and Customers
14.3. Parkinson's Disease Treatments Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boehringer Ingelheim
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Impax
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Abbvie
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Valeant Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Lundbeck
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sun Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Wockhardt
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Acadia
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. UCB
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
